title: Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
abstract: OBJECTIVE
  To assess the efficacy and toxicity of an immunotherapy regimen combining subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha (IFN) in patients with metastatic renal cell carcinoma (MRCC).
  
  
  METHODS
  The present study included 86 patients with MRCC. Data on treatment toxicity and efficacy (responses rates and overall survival) were collected on a hospital database. Treatment consisted of 6-week cycles repeated every 2 months for a maximum of 3 cycles. Each cycle included SC IL-2 20 x 10 MIU/m2 3 times/wk on weeks 1 and 4; 5 x 10 MIU/m2 3 times/wk on weeks 2, 3, 5, and 6, in combination with IFN 6 x 10 MIU/m2 once weekly on weeks 1 and 4; and 3 times/wk on weeks 2, 3, 5, and 6.
  
  
  RESULTS
  Seventy (82%) and 71 (83%) patients received more than 80% of the planned doses of IL-2 and IFN during the first cycle, respectively. Ten patients had to stop therapy before the end of the first cycle because of excessive toxicity (7 patients) or rapidly progressive disease (3 patients). Only 17 (28%) proceeded to the second cycle. Main toxicities included fever and asthenia in 86 (100%) patients, nausea/emesis in 83 (96%) patients, skin disorders in 69 (80%) patients, hypotension in 56 (65%) patients, and diarrhea in 50 (58%) patients. Sixty-seven (78%) patients developed at least one episode of grade 3 toxicity. Objective responses were observed in 13 patients, including 4 complete and 9 partial responses (15%; 95% confidence interval, 9.5-20.5%). After a median follow-up of 45 months, the median time to progression was 4 months (range, 1-41) and the median survival was 14 months (range, 1-89).
  
  
  CONCLUSIONS
  Only a small subset of patients with MRCC is likely to benefit from treatment with IL-2 and IFN. As toxicity is significant, the refinement of predictive variables for sensitivity to immunotherapy is mandatory.
authors.affiliation: Centre Val d'Aurelle, Montpellier, France. stculine@valdorel.fnclcc.fr
authors.forename: Stéphane
authors.initials: S
authors.lastname: Culine
authors.forename: François
authors.initials: F
authors.lastname: Iborra
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mottet
authors.forename: Christophe
authors.initials: C
authors.lastname: Avancès
authors.forename: Bertrand
authors.initials: B
authors.lastname: de Graeve
authors.forename: Pascal
authors.initials: P
authors.lastname: Volpé
authors.forename: Jacques
authors.initials: J
authors.lastname: Vignoud
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bringer
authors.forename: Michel
authors.initials: M
authors.lastname: Marroncle
authors.forename: Loïc
authors.initials: L
authors.lastname: Le Pellec
authors.forename: Didier
authors.initials: D
authors.lastname: Ayuso
authors.forename: Eric
authors.initials: E
authors.lastname: Jansen
authors.forename: Antoine
authors.initials: A
authors.lastname: Faix
authors.forename: Xavier
authors.initials: X
authors.lastname: Rebillard
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005602:France; D006801:Humans; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2